San Antonio Cancer Institute - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 41

San Antonio Cancer Institute – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “San Antonio Cancer Institute - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- San Antonio Cancer Institute - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of San Antonio Cancer Institute human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of San Antonio Cancer Institute with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the San Antonio Cancer Institute’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate San Antonio Cancer Institute’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of San Antonio Cancer Institute in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the San Antonio Cancer Institute’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with San Antonio Cancer Institute.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of San Antonio Cancer Institute and identify potential opportunities in those areas.

List of Tables
List of Figures
San Antonio Cancer Institute Snapshot
Key Information
Key Facts
San Antonio Cancer Institute – Research and Development Overview
Key Therapeutic Areas
San Antonio Cancer Institute – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
San Antonio Cancer Institute – Pipeline Products Glance
San Antonio Cancer Institute Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
San Antonio Cancer Institute – Drug Profiles
G3139 + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Genasense + FOLFOX4
Product Description
Mechanism of Action
R&D Progress
MGI 114
Product Description
Mechanism of Action
R&D Progress
Oblimersen Sodium + Fluorouracil + Leucovorin Calcium + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Oblimersen Sodium + Fluorouracil + Leucovorin Calcium + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
tipifarnib + trastuzumab
Product Description
Mechanism of Action
R&D Progress
Trastuzumab + Tipifarnib
Product Description
Mechanism of Action
R&D Progress
Carbendazim
Product Description
Mechanism of Action
R&D Progress
COL-3
Product Description
Mechanism of Action
R&D Progress
Gemcitabine hydrochloride + Tipifarnib
Product Description
Mechanism of Action
R&D Progress
irinotecan hydrochloride + mitomycin C
Product Description
Mechanism of Action
R&D Progress
Irinotecan Hydrochloride + Pemetrexed Disodium
Product Description
Mechanism of Action
R&D Progress
pemetrexed disodium
Product Description
Mechanism of Action
R&D Progress
Temozolomide
Product Description
Mechanism of Action
R&D Progress
Temsirolimus
Product Description
Mechanism of Action
R&D Progress
San Antonio Cancer Institute – Pipeline Analysis
San Antonio Cancer Institute – Pipeline Products by Therapeutic Class
San Antonio Cancer Institute Pipeline Products By Target
San Antonio Cancer Institute – Pipeline Products by Route of Administration
San Antonio Cancer Institute – Pipeline Products by Molecule Type
San Antonio Cancer Institute – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• International Military and Government Helicopter Survey
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition